Statement: The majority of patients in the primary trial experienced an adverse event.
Primary_evidence: Adverse Events 1:   Total: 24/32 (75.00%)   Disseminated intravascular coagulation * 1/32 (3.13%)   Febrile neutropenia * 1/32 (3.13%)   Adrenal insufficiency * 1/32 (3.13%)   Endocrine disorder * 1/32 (3.13%)   Chills * 1/32 (3.13%)   Fatigue * 1/32 (3.13%)   Fever * 1/32 (3.13%)   Multi-organ failure * 1/32 (3.13%)   Hepatic failure * 1/32 (3.13%)   Infection * 1/32 (3.13%)   Sepsis * 1/32 (3.13%)